Cargando…

Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia

INTRODUCTION: Prostate cancer (PCa) is one of the most common malignancies in men worldwide. Serum prostate specific antigen (PSA) level has been extensively used as a biomarker to detect PCa. However, PSA is not cancer-specific and various non-malignant conditions, including benign prostatic hyperp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Rambla, Clara, Puchades-Carrasco, Leonor, García-Flores, María, Rubio-Briones, José, López-Guerrero, José Antonio, Pineda-Lucena, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533870/ https://www.ncbi.nlm.nih.gov/pubmed/28804274 http://dx.doi.org/10.1007/s11306-017-1194-y

Ejemplares similares

Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
por: Gómez-Cebrián, Nuria, et al.
Publicado: (2019)

Metabolomics Applications in Precision Medicine: An Oncological Perspective
por: Puchades-Carrasco, Leonor, et al.
Publicado: (2017)

Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches
por: Gómez-Cebrián, Nuria, et al.
Publicado: (2022)

Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia
por: Amante, Eleonora, et al.
Publicado: (2022)

Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
por: Xu, Bei, et al.
Publicado: (2021)

Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia
por: Yu, Haining, et al.
Publicado: (2015)

Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer
por: Puchades-Carrasco, Leonor, et al.
Publicado: (2016)

Benign Prostatic Hyperplasia
Publicado: (2015)

Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia
por: Hsiao, Chun-Jen, et al.
Publicado: (2016)

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
por: Masumori, Naoya
Publicado: (2011)

Acute urinary tract infection in patients with underlying benign prostatic hyperplasia and prostate cancer
por: Tolani, Musliu Adetola, et al.
Publicado: (2020)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia
por: Jia, Gaozhen, et al.
Publicado: (2017)

Persistence to Medications for Benign Prostatic Hyperplasia/Benign Prostatic Obstruction-Associated Lower Urinary Tract Symptoms in the ASL TO4 Regione Piemonte (Italy)
por: Armando, Lucrezia Greta, et al.
Publicado: (2022)

The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms
por: Yu, Seong Hyeon, et al.
Publicado: (2022)

Prostatitis and benign prostatic hyperplasia: emerging infectious diseases?
por: Hennenfent, B
Publicado: (1997)

Zinc status in benign prostatic hyperplasia and prostate carcinoma
por: Wiwanitkit, Somsri, et al.
Publicado: (2012)

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Botulinum toxin and benign prostatic hyperplasia
por: Ng, Lay Guat
Publicado: (2018)

Solving the benign prostatic hyperplasia puzzle
por: Foo, Keong Tatt
Publicado: (2016)

Tissue microenvironment and benign prostatic hyperplasia
por: Wei, Xing, et al.
Publicado: (2019)

Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk
por: Hung, S-C, et al.
Publicado: (2013)

Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management
por: Muruganandham, K., et al.
Publicado: (2007)

Large bowel obstruction caused by urinary retention from benign prostate hyperplasia
por: Fujisaki, Tomohiro, et al.
Publicado: (2018)

Lower urinary tract symptoms and benign prostatic hyperplasia: From research to bedside
por: Goel, Apul
Publicado: (2019)

Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia
por: Fu, Shuang, et al.
Publicado: (2018)

Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma
por: Christudoss, Pamela, et al.
Publicado: (2011)

Expression and Localization of Aquaporins in Benign Prostate Hyperplasia and Prostate Cancer
por: Hwang, Insang, et al.
Publicado: (2012)

Rare Variant of Carcinoma Prostate Masquerading as Benign Prostatic Hyperplasia
por: Khanduri, Sachin, et al.
Publicado: (2019)

Prostate sarcomas: A radiological mimic for benign prostatic hyperplasia
por: Whish-Wilson, Thomas, et al.
Publicado: (2020)

Prostate embolization in the treatment of benign prostatic hyperplasia: what’s the point?
por: Nunes, Thiago Franchi, et al.
Publicado: (2021)

Heat Shock Proteins in Benign Prostatic Hyperplasia and Prostate Cancer
por: Ratajczak, Weronika, et al.
Publicado: (2022)

Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer
por: Glaser, Alexander, et al.
Publicado: (2022)

Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients
por: Haj-Ahmad, Taha A, et al.
Publicado: (2014)

Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2017)

Linking Pre-Diabetes with Benign Prostate Hyperplasia. IGFBP-3: A Conductor of Benign Prostate Hyperplasia Development Orchestra?
por: Protopsaltis, Ioannis, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_popmhpr5unubroosmsdu71n229